secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2021-10-04T23:59:59+00:00
Accession:  0001564590-21-049869
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Medical Concepts appoints Betsy Hanna and Deepti Jain to Board of Directors
--------------------------------------------------------------------------------

- Appointments effective October 1, 2021; Hanna as Class II director (term to 2023), Jain as Class I (term to 2022).
- Hanna to serve on Compensation and NCG Committees; Jain on Audit and NCG Committees.
- Hanna is President/CEO of Clinical Genomics, former J&J Vision Care VP; MBA from Harvard.
- Jain was President of IngenioRX (Anthem), COO of Pharmacy Solutions; MBA from Baruch College.
- Both determined independent under Nasdaq rules; no related-party transactions disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000156459021049869/0001564590-21-049869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000156459021049869/tmci-8k_20210930.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-049869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer